Zimmer Biomet (ZBH)
(Delayed Data from NYSE)
$116.17 USD
+0.71 (0.61%)
Updated Sep 3, 2024 04:00 PM ET
After-Market: $116.20 +0.03 (0.03%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$116.17 USD
+0.71 (0.61%)
Updated Sep 3, 2024 04:00 PM ET
After-Market: $116.20 +0.03 (0.03%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth F Momentum C VGM
Zacks News
Zimmer Biomet is a leading musculoskeletal healthcare company that designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. With operations in over 25 countries, Zimmer markets products in more than 100 countries. In 2015, Zimmer Holdings, Inc. (the legacy company) acquired Biomet, Inc. to form a new consolidated company.
Zimmer Biomet Solid on Global Prospects Despite Price Pressure
by Zacks Equity Research
Zimmer Biomet (ZBH) has been working to strengthen foothold in emerging markets. However, the company has been facing continued pricing pressure.
RTI Surgical Buys Paradigm Spine, Adds Coflex to Portfolio
by Zacks Equity Research
RTI Surgical's (RTIX) acquisition of Paradigm Spine aligns with the former's goal of expanding its spine portfolio.
Zimmer Biomet (ZBH) Jumps: Stock Rises 6.4%
by Zacks Equity Research
Zimmer Biomet (ZBH) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Zimmer Biomet (ZBH) Q4 Earnings Meet Estimates, Revenues Top
by Zacks Equity Research
Zimmer Biomet (ZBH) sees strength in the Asia Pacific and EMEA regions as well as in the Spine & CMF business in Q4.
Zimmer Biomet (ZBH) Meets Q4 Earnings Estimates
by Zacks Equity Research
Zimmer (ZBH) delivered earnings and revenue surprises of 0.00% and 0.54%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
ZBH & IDXX Q4 Earnings on Feb 1: Here are the Key Predictions
by Zacks Equity Research
The global medical device space is passing through a rewarding phase for a considerable period of time in terms of research and development (R&D) plus regulatory progress.
Medical Products Industry Outlook: Plenty of Upside Left
by Zacks Equity Research
The growing adoption of AI, Medical Mechatronics & Robotics has lent the Medical Products industry a competitive edge in the broader medical market.
Can Zimmer Biomet (ZBH) Grow on Hip Business in Q4 Earnings?
by Zacks Equity Research
Within Hip business, we expect Zimmer Biomet (ZBH) to experience a strong uptick in the Asia-Pacific region.
Zimmer Biomet (ZBH) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Zimmer (ZBH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Zimmer Biomet (ZBH) a Great Stock for Value Investors?
by Zacks Equity Research
Let's see if Zimmer Biomet (ZBH) stock is a good choice for value-oriented investors right now from multiple angles.
Zimmer Biomet (ZBH) Thrives on New Projects, APAC Growth
by Zacks Equity Research
Zimmer Biomet (ZBH) is performing well on the back of its two largest commercial projects, namely the Persona Revision system and the Rosa robotics knee application.
Zimmer Biomet Rides on New Operational Plan Amid Several Woes
by Zacks Equity Research
In order to tackle several near-term concerns, Zimmer Biomet (ZBH) of late begins to review its 2018 operating plan to clearly define its go-forward strategies in a number of thrust areas.
Should Value Investors Pick Zimmer Biomet (ZBH) Stock?
by Zacks Equity Research
Is Zimmer Biomet (ZBH) a great pick from the value investor's perspective right now? Read on to know more.
Zimmer (ZBH) Down 7.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights: Comcast, ConocoPhillips, Delta Air Lines, ServiceNow and Zimmer Biomet
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Comcast, ConocoPhillips, Delta Air Lines, ServiceNow and Zimmer Biomet
Top Research Reports for Comcast, ConocoPhillips & Delta Air Lines
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Comcast (CMCSA), ConocoPhillips (COP), and Delta Air Lines (DAL).
Zimmer Biomet (ZBH) Q3 Earnings Top Estimates, Margins Down
by Zacks Equity Research
We are encouraged by Zimmer Biomet's (ZBH) consistent effort in product renovation through research and development.
Zimmer Biomet (ZBH) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Zimmer (ZBH) delivered earnings and revenue surprises of 1.87% and 0.11%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Zimmer Biomet (ZBH) This Earnings Season?
by Zacks Equity Research
Focusing on areas like quality correction, supply recovery and product introductions, Zimmer Biomet (ZBH) is expected to see robust top-line numbers at S.E.T. arm in Q3.
Zimmer Biomet (ZBH) Q3 Earnings Preview: What's in the Cards?
by Zacks Equity Research
Zimmer (ZBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zimmer Biomet (ZBH) Q2 Earnings Top Estimates, Margins Drop
by Zacks Equity Research
The improvement within Zimmer Biomet's (ZBH) global Knee and Hip sales performance and ongoing growth within the Asia Pacific region are encouraging.
Zimmer Biomet (ZBH) Beats on Q2 Earnings & Revenue Estimates
by Zacks Equity Research
Zimmer Biomet (ZBH) rides on strength in Knee and Hip segments in Q2.
Zimmer Biomet (ZBH) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Zimmer (ZBH) delivered earnings and revenue surprises of 2.13% and 0.65%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Zimmer Biomet (ZBH) in Q2 Earnings?
by Zacks Equity Research
Focusing on the thrust areas like quality correction, supply recovery efforts and product introductions, Zimmer Biomet (ZBH) is expected to retain robust top-line numbers within its S.E.T. arm.
Zimmer Biomet (ZBH) Down 2.9% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Zimmer Biomet (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.